Biotransformation and Metabolite Elucidation of Xenobiotics
Regular price
€128.99
14 days return policy
Shipping & Delivery
ADMET
Ala Nassar
biotransformation and metabolite elucidation of xenobiotics
Category=PSAG
eq_bestseller
eq_isMigrated=1
eq_isMigrated=2
eq_nobargain
eq_non-fiction
eq_science
metabolite identification
xenobiotics
Product details
- ISBN 9780470504789
- Weight: 644g
- Dimensions: 163 x 241mm
- Publication Date: 12 Nov 2010
- Publisher: John Wiley & Sons Inc
- Publication City/Country: US
- Product Form: Hardback
Secure
checkout
Fast Shipping
Easy returns
The goal of this book is to improve the readers' knowledge of metabolite elucidation in drug metabolism by exposing them to in depth coverage of the biotransformation of xenobiotics, strategies for identifying and characterizing metabolites, FDA guidelines, and case studies on how to improve the decision-making process in structural modification of drug candidates to reduce toxicity.
The book consists of 8 chapters; it first provides an introduction on biotransformation of xenobiotics, and then presents modern approaches and strategies for dealing with metabolite characterization, using tools such as LC-MS, H-D exchange, stable isotopes LC-MS-NMR, and radiolabeled compounds. Also, strategies for dealing with reactive intermediates in drug discovery and development are presented as well as case studies on improving the decision-making process in the structural modification of drug candidates. The last chapter discusses the regulatory perspectives of safety testing of drug metabolites and why, how, and when to test their safety.
ALA F. NASSAR, PHD, has worked in the pharmaceutical industry for more than ten years. For over five years, Dr. Nassar oversaw the drug metabolism and bioanalytical department at Vion Pharmaceuticals, working in these key areas of drug discovery and development. One principal area of his research involved understanding how structure modification can improve the ADME profile for new chemical entities as they advance toward clinical candidacy. He identified and subsequently patented pharmacologically active metabolites of Nexavar (sorafenib), and recently identified the pharmacologically active metabolite of Onrigin (laromustine), and is in the process of seeking a patent on this discovery. Dr. Nassar has more than fifty publications in journal articles and book chapters; and has taught and coordinated several courses on bioanalytical chemistry, LC-MS, and drug metabolism to share his experience with other scientists in the field. Currently, he is the Director of the Mass Spectrometry Facility and Research Assistant Professor at Brandeis University.
